Targeting FOXA1 through SKP2 inhibition (SZL P1‐41) can restore FOXA1 levels and luminal positive phenotypes enhancing therapeutic sensitivity in advanced stages of PCa. Here, SKP2 is linked to posterior cortical atrophy.